Premarin (Conjugated Estrogens)

Premarin (Conjugated Estrogens) is a female hormone and is usually given to women who no longer produce the proper amount. It is used to reduce menopause symptoms (e.g., hot flashes, vaginal dryness), to prevent bone loss (osteoporosis) in people at high risk, or to treat certain cancers in men and women (e.g., certain types of metastatic breast cancer). Premarin (conjugated estrogens) is extracted from the urine of pregnant mares (female horses). It is also used by many women in Israel. Premarin (Conjugated Estrogens) is a female hormone and is usually given to women who no longer produce the proper amount. It is new to diminish menopause symptoms (e.g., hot flashes, vaginal dryness), to prevent bone loss (osteoporosis) in people at high risk, or to treat sure cancers in men and women (e.g., sure types of metastatic breast cancer).

Doses are adjusted depending on the severity of symptoms and responsiveness of the endometrium. Doses of 0.15 mg have been used in girls and are associated with the onset of development of secondary sex characteristics. Doses as low as NETA 0.5 mg, NET 0.35 mg, MPA 2.5 mg, levonorgesterel 0.25 mg, and dydrogesterone 5 mg have been used previously in continuous uninterrupted HRT regimens. Dose-response analyses indicated that the lowest effective concentration of CEEs exerted the maximal neurotrophic effect with greatest potency occurring in hippocampal and occipital cortex neurons. CEES induced highly significant neuroprotection against beta amyloid(25-35), hydrogen peroxide and glutamate-induced toxicity.

Women with breast or bone cancer are especially at risk and should stop taking Premarin immediately if they develop hypercalcemia. In addition, women with the opposite problem—hypocalcemia, or a severe decrease of calcium in the blood—should use Premarin with caution. Women experiencing menopausal symptoms are encouraged to speak with their health care professionals to determine whether hormone therapy might be the right treatment option for them. Women on estrogen replacement therapy, taken alone or in combination with a progestin, have been reported in some studies to have an increased risk of thrombophlebitis, and/or thromboembolic disease. You should alert the physician if any of the following symptoms occur: changes in vision, tightness in chest, shortness of breath, severe pain in one or both legs, numbness affecting one side or one part of the body, and first migraine.